BCRX•benzinga•
Biocryst Pharmaceuticals Expects To Approach Quarterly Positive EPS And Positive Cash Flow In The Second Half Of 2025, And To Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 24, 2025 by benzinga